Attached files
| file | filename |
|---|---|
| EX-3.1 - EX-3.1 - Cardlytics, Inc. | d338035dex31.htm |
| EX-10.11 - EX-10.11 - Cardlytics, Inc. | d338035dex1011.htm |
| EX-10.7 - EX-10.7 - Cardlytics, Inc. | d338035dex107.htm |
| EX-10.4 - EX-10.4 - Cardlytics, Inc. | d338035dex104.htm |
| EX-10.3 - EX-10.3 - Cardlytics, Inc. | d338035dex103.htm |
| EX-10.2 - EX-10.2 - Cardlytics, Inc. | d338035dex102.htm |
| EX-10.1 - EX-10.1 - Cardlytics, Inc. | d338035dex101.htm |
| EX-5.1 - EX-5.1 - Cardlytics, Inc. | d338035dex51.htm |
| EX-4.1 - EX-4.1 - Cardlytics, Inc. | d338035dex41.htm |
| EX-1.1 - EX-1.1 - Cardlytics, Inc. | d338035dex11.htm |
| S-1/A - FORM S-1/A - Cardlytics, Inc. | d338035ds1a.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Amendment No. 1 on Form S-1 to Registration Statement No. 333-222531 of our report dated April 5, 2017 (May 12, 2017 as to the effects of the Series G and G’ Stock financing described in Note 16; January 29, 2018 as to the effects of the Charter Amendment described in Note 16) relating to the financial statements of Cardlytics, Inc. and its wholly-owned subsidiary appearing in the Prospectus, which is part of this Registration Statement, and to the reference to us under the heading “Experts” in such Prospectus.
/s/ DELOITTE & TOUCHE LLP
Atlanta, Georgia
January 29, 2018